simendan has been researched along with rolipram in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| De Santis, V; Mazzesi, G; Miraldi, F; Ozdem, SS; Papalia, U; Puddu, PE; Tritapepe, L; Usta, C; Vitale, D | 1 |
| Andersen, GØ; Ata, SH; Dahl, CP; Levy, FO; Orstavik, O; Osnes, JB; Qvigstad, E; Riise, J; Skomedal, T | 1 |
| Abella, LMR; Gergs, U; Hoffmann, R; Hofmann, B; Neumann, J | 1 |
3 other study(ies) available for simendan and rolipram
| Article | Year |
|---|---|
Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae.
Topics: Adult; Aged; Cardiotonic Agents; Coronary Artery Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electric Stimulation; Female; Heart Atria; Heart Valve Diseases; Humans; Hydrazones; Male; Middle Aged; Myocardial Contraction; Pyridazines; Rheumatic Heart Disease; Rolipram; Simendan; Troponin C | 2004 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Milrinone; Myocardial Contraction; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Pyridazines; Quinolines; Quinolones; Rats, Wistar; Rolipram; Simendan; Thiadiazines | 2014 |
Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium.
Topics: Animals; Atrial Fibrillation; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Mice; Myocardial Contraction; Phosphorylation; Propranolol; Rolipram; Simendan | 2023 |